Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
BOSTON - Vor Bio (NASDAQ:VOR), whose stock has surged over 137% in the past year and 20% in the last week alone, announced Monday that clinical data from a Phase 3 study of telitacicept in adults with primary Sjögren’s disease will be presented at the upcoming ACR Convergence 2025 conference in Chicago. According to InvestingPro data, the company, currently valued at $230 million, shows promising momentum despite being currently undervalued based on Fair Value analysis.
The late-breaking poster presentation, scheduled for October 28, will showcase results from a multicenter, randomized, double-blind, placebo-controlled trial conducted in China by Vor’s collaborator RemeGen Co., Ltd (HKEX:9995, SHA:688331).
Earlier this month, RemeGen submitted a Biologics License Application to China’s National Medical Products Administration for telitacicept in primary Sjögren’s disease. If approved, this would become the drug’s fourth indication in China, where it is already approved for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis. InvestingPro analysis reveals that while Vor Bio maintains strong liquidity with a current ratio of 3.49, the company is rapidly utilizing its cash reserves for development activities.
Telitacicept is a recombinant fusion protein designed to inhibit BLyS and APRIL, two cytokines involved in B cell and plasma cell survival. By targeting these pathways, the therapy aims to reduce autoreactive B cells and autoantibody production that drive autoimmune diseases.
Sjögren’s disease is a chronic autoimmune condition characterized by dry eyes, dry mouth, fatigue, and pain. It can also cause systemic complications affecting multiple organs. Despite being one of the most common rheumatic autoimmune diseases, it remains underdiagnosed and has no approved systemic disease-modifying therapies.
Vor Bio is currently conducting a global Phase 3 trial of telitacicept in generalized myasthenia gravis across multiple regions to support potential approvals in the United States, Europe, and Japan.
This information is based on a press release statement from Vor Bio. Investors looking to track the company’s progress can mark their calendars for November 7, 2025, when Vor Bio is scheduled to report its next earnings. For comprehensive analysis including 12 additional ProTips and detailed financial metrics, visit InvestingPro, where you’ll find an in-depth Pro Research Report on Vor Bio among 1,400+ top stocks.
In other recent news, Vor Biopharma Inc. has announced a 1-for-20 reverse stock split of its common stock, which became effective at 5:00 p.m. Eastern Time. This move was approved by stockholders at a special meeting and will result in every 20 shares being converted into one share, with cash payments made for any fractional shares. Stifel has upgraded Vor Biopharma from Hold to Buy, raising its price target to $55.00, citing increased confidence in the company’s telitacicept drug prospects for autoimmune diseases. The company is also set to present 48-week clinical data from a Phase 3 study of telitacicept in adults with generalized myasthenia gravis at an upcoming medical conference. Additionally, Vor Biopharma has appointed Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer, bringing over 20 years of experience in medical affairs and R&D. Lastly, the company filed a preliminary prospectus for the potential resale of up to 50,999,999 shares of its common stock by selling stockholders, involving shares issuable to a subsidiary of RemeGen Co. Ltd. and private placement investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.